A Phase 3 interventional study of Irinotecan + 5 FU + folinic acid and Folinic Acid + 5 FU in Colorectal Neoplasms and Liver Neoplasms, sponsored by Pfizer. Completed at 66 sites in 16 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-09-28.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 200 studies testing irinotecan in Colorectal Neoplasms — 25 open to participants now, 32 under way, 6 of them phase 3. Irinotecan · Colorectal Neoplasms.
Among the 200 studies testing irinotecan in Colorectal Neoplasms, this one is the 14th largest by enrollment of the 182 interventional ones that give a count, is one of 12 that started in 2001, is one of 26 in phase 3, and was the 47th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →25 of the 200 studies testing irinotecan in Colorectal Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
Gruppo Oncologico Italia Meridionale · Sites in Italy
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18–80
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
200 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 139 · Phase 3 28 · Phase 4 2
First in 1996; this study’s year is marked. 12 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 321 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 47 across the 182 interventional studies. Of the 131 that completed or were terminated, 27 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 200 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
73 studies in Colorectal Neoplasms by Pfizer: 6 open now, 14 under way, 3 of them phase 3. Of 58 finished, 28 (48%) have results posted.
Among the 73 studies in Colorectal Neoplasms by Pfizer, this one is the 10th largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2001, is one of 9 in phase 3, and was the 12th registered.
Pfizer’s Colorectal Neoplasms studies by the year they started, since 1999.
7 of the studies testing irinotecan in Colorectal Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT06321081Beijing HospitalICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC | 2026-12-30 |
| NCT07229846Yanqiao ZhangA Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | 2027-02 |
| NCT05391126Reema A. PatelGENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care | 2027-05 |
| NCT07570914Tianjin Medical University Cancer Institute and HospitalHepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | 2027-05-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 200 studies testing irinotecan in Colorectal Neoplasms, from their registry updates:
Among Pfizer’s 73 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
To see if Disease Free Survival (DFS) is improved when complete surgical resection of liver metastases (R0) is followed by chemotherapy with CPT-11 and 5-FU/FA as FOLFIRI regimen, compared to 5-FU/FA alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Irinotecan + 5 FU + folinic acid
Drug: Folinic Acid + 5 FU
Drug pages: Irinotecan · Fluorouracil · Leucovorin
irinotecan 180 mg/m2 folinic acid 400 mg/m2 (DL) followed by 5 FU bolus 400 mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
Drug pages: Leucovorin · Fluorouracil
folinic acid 400 mg/m2(DL) followed by bolus 5 FU 400mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
Disease Free Survival (DFS)
time interval between the date of randomization and the earliest date of local, regional or distant relapse, or death due to cancer.
Time frame: last tumor assessment date or cut-off date, whichever is earlier.
Overall Survival Rates
Probability of being alive was calculated in a yearly increment.
Time frame: Median follow-up time (42 months)
study was conducted at 66 centers.
| Milestone | 5-FU/FA | Irinotecan + 5-FU/FA |
|---|---|---|
| Started | 160 | 161 |
| Treated | 153 | 153 |
| Completed | 125 | 115 |
| Not completed | 35 | 46 |
| Withdrew: Adverse event | 3 | 8 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 12 |
| Withdrew: Relapse | 15 | 7 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Specified by site | 4 | 9 |
| Withdrew: Randomized not treated | 7 | 8 |
time interval between the date of randomization and the earliest date of local, regional or distant relapse, or death due to cancer.
| months | 5-FU/FA | Irinotecan + 5-FU/FA |
|---|---|---|
| Disease Free Survival (DFS) | 21.6 (14.6 to 30.4) | 24.7 (18.7 to 38.9) |
Probability of being alive was calculated in a yearly increment.
| survival rate | 5-FU/FA | Irinotecan + 5-FU/FA |
|---|---|---|
| 12 months | 0.961 | 0.973 |
| 24 months | 0.845 | 0.881 |
| 36 months | 0.716 | 0.727 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 5-FU/FA | — | 15/152 (9.9%) | 146/152 (96.1%) |
| Irinotecan + 5-FU/FA | — | 32/154 (20.8%) | 150/154 (97.4%) |
| Event | 5-FU/FA | Irinotecan + 5-FU/FA |
|---|---|---|
| Diarrhoea NOSGastrointestinal disorders | 0/152 | 7/154 |
| Deep vein thrombosisVascular disorders | 1/152 | 5/154 |
| DizzinessNervous system disorders | 0/152 | 3/154 |
| NeutropeniaBlood and lymphatic system disorders | 0/152 | 3/154 |
| Abdominal pain NOSGastrointestinal disorders | 2/152 | 1/154 |
| Intestinal obstruction NOSGastrointestinal disorders | 2/152 | 0/154 |
| Vomiting NOSGastrointestinal disorders | 2/152 | 2/154 |
| Chest painGeneral disorders | 0/152 | 2/154 |
| DehydrationMetabolism and nutrition disorders | 0/152 | 2/154 |
| Liver abscessInfections and infestations | 0/152 | 2/154 |
| Event | 5-FU/FA | Irinotecan + 5-FU/FA |
|---|---|---|
| NauseaGastrointestinal disorders | 91/152 | 116/154 |
| Diarrhea, NOSGastrointestinal disorders | 80/152 | 98/154 |
| AlopeciaSkin and subcutaneous tissue disorders | 28/152 | 69/154 |
| Vomiting, NOSGastrointestinal disorders | 37/152 | 64/154 |
| NeutropeniaBlood and lymphatic system disorders | 25/152 | 62/154 |
| AstheniaGeneral disorders | 48/152 | 53/154 |
| ConstipationGastrointestinal disorders | 30/152 | 46/154 |
| Abdominal pain, NOSGastrointestinal disorders | 40/152 | 41/154 |
| StomatitisGastrointestinal disorders | 40/152 | 34/154 |
| FatigueGeneral disorders | 28/152 | 34/154 |
| Age Continuous(years) | 5-FU/FA | Irinotecan + 5-FU/FA | Total |
|---|---|---|---|
| Median | 61 (34 to 76) | 63 (27 to 75) | 62 (27 to 76) |
| Sex: Female, Male(Participants) | 5-FU/FA | Irinotecan + 5-FU/FA | Total |
|---|---|---|---|
| Female | 53 | 63 | 116.0 |
| Male | 100 | 90 | 190.0 |
The record gives a start of Dec 2001, a primary completion of Feb 2008 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Irinotecan · Fluorouracil · Leucovorin